Threohydrobupropion (original) (raw)
Threohydrobupropion (developmental code names BW 494, BW A494U) is a substituted amphetamine derivative—specifically a β-hydroxyamphetamine—and a major active metabolite of the antidepressant drug bupropion (Wellbutrin). Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator, with its metabolites contributing substantially to its activities. Threohydrobupropion exists as two isomers, (1R,2R)-threohydrobupropion and (1S,2S)-threohydrobupropion. Other metabolites of bupropion include hydroxybupropion and erythrohydrobupropion.
| Property | Value |
|---|---|
| dbo:abstract | Threohydrobupropion (developmental code names BW 494, BW A494U) is a substituted amphetamine derivative—specifically a β-hydroxyamphetamine—and a major active metabolite of the antidepressant drug bupropion (Wellbutrin). Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator, with its metabolites contributing substantially to its activities. Threohydrobupropion exists as two isomers, (1R,2R)-threohydrobupropion and (1S,2S)-threohydrobupropion. Other metabolites of bupropion include hydroxybupropion and erythrohydrobupropion. Information on the pharmacological actions of threohydrobupropion is scarce. In any case, it is about 20% as pharmacologically potent as bupropion and in the range of 20 to 50% as potent as bupropion in mouse models of depression. Moreover, threohydrobupropion has been reported to weakly inhibit the reuptake of norepinephrine, dopamine, and serotonin with rat IC50 or Ki values of 16 μM, 47 μM, and 67 μM, respectively. These values can be compared to rat values with bupropion of 1,400 nM, 570 nM, and 19,000 nM, respectively. Besides monoamine reuptake inhibition, threohydrobupropion has also been reported to inhibit α3β4 nicotinic acetylcholine receptors, with an IC50 value of 14 μM. Threohydrobupropion circulates at higher concentrations than bupropion during bupropion therapy, similarly to hydroxybupropion but in contrast to erythrohydrobupropion—which circulates at similar concentrations as bupropion. The plasma protein binding of threohydrobupropion is 42%. Threohydrobupropion is formed from bupropion via reduction of the ketone group by 11β-hydroxysteroid dehydrogenase-1 and aldo-keto reductases. It can also be formed from bupropion by carbonyl reductases. The compound is metabolized by the cytochrome P450 enzymes CYP2B6 and CYP2C19 into threo-4'-hydroxy-hydrobupropion and by various glucuronosyltransferase enzymes into glucuronide conjugates. Its elimination half-life is approximately 37 hours. Dry mouth during bupropion therapy has been associated with threohydrobupropion concentrations. Administration of threohydrobupropion in mice produces seizures at sufficiently high doses similarly to bupropion and other metabolites. Threohydrobupropion is a CYP2D6 inhibitor and accounts for about 21% of CYP2D6 inhibition during bupropion therapy, with hydroxybupropion accounting for 65% and erythrohydrobupropion accounting for 9%. (en) |
| dbo:casNumber | 99102-04-2 |
| dbo:chEMBL | 1304 |
| dbo:pubchem | 445 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Threohydrobupropion.svg?width=300 |
| dbo:wikiPageID | 71616465 (xsd:integer) |
| dbo:wikiPageLength | 7833 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1114277803 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Potency_(pharmacology) dbr:Enzyme_inhibitor dbr:Metabolite dbr:Hydroxybupropion dbr:Cytochrome_P450 dbr:Substituted_amphetamine dbr:Reuptake_inhibitor dbc:Chlorobenzenes dbc:Human_drug_metabolites dbc:Secondary_alcohols dbc:Secondary_amines dbr:Erythrohydrobupropion dbr:Structural_isomer dbr:Elimination_half-life dbr:Enzyme dbc:Nicotinic_antagonists dbr:Animal_model dbr:Antidepressant dbr:Ketone dbc:Phenylethanolamines dbr:Bupropion dbr:Active_metabolite dbr:Aldo-keto_reductase dbc:Antidepressants dbr:Alpha-3_beta-4_nicotinic_receptor dbr:Norepinephrine dbr:Norepinephrine–dopamine_reuptake_inhibitor dbr:Glucuronidation dbr:Glucuronide dbr:Glucuronosyltransferase dbr:Redox dbc:Convulsants dbc:Serotonin–norepinephrine–dopamine_reuptake_inhibitors dbc:Substituted_amphetamines dbc:Tert-butyl_compounds dbr:Hydroxylation dbr:Dopamine dbr:CYP2B6 dbr:CYP2C19 dbr:CYP2D6 dbr:Metabolism dbr:Seizure dbr:Serotonin dbr:Nicotinic_acetylcholine_receptor dbr:Reuptake dbr:Plasma_protein_binding dbr:Dry_mouth dbr:Pharmacological_action dbr:Chemical_derivative dbr:Conjugate_(biochemistry) dbr:11β-hydroxysteroid_dehydrogenase-1 dbr:Carbonyl_reductase dbr:Monoamine_reuptake_inhibition dbr:Negative_allosteric_modulator dbr:Β-hydroxyamphetamine |
| dbp:c | 13 (xsd:integer) |
| dbp:casNumber | 99102 (xsd:integer) |
| dbp:chembl | 1304 (xsd:integer) |
| dbp:chemspiderid | 432 (xsd:integer) |
| dbp:cl | 1 (xsd:integer) |
| dbp:eliminationHalfLife | 133200.0 |
| dbp:h | 20 (xsd:integer) |
| dbp:iupacName | 2 (xsd:integer) |
| dbp:metabolism | Hydroxylation , glucuronidation (en) |
| dbp:n | 1 (xsd:integer) |
| dbp:o | 1 (xsd:integer) |
| dbp:proteinBound | 42.0 |
| dbp:pubchem | 445 (xsd:integer) |
| dbp:smiles | CCNCC (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | NDPTTXIBLSWNSF-UHFFFAOYSA-N (en) |
| dbp:synonyms | threo-Hydrobupropion; Threohydroxybupropion; BW 494; BW A494U; threo-3-Chloro-N-tert-butyl-β-hydroxy-α-methylphenethylamine; threo-3-Chloro-N-tert-butyl-β-hydroxyamphetamine (en) |
| dbp:width | 200 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Expert_needed dbt:Infobox_drug dbt:Multiple_issues dbt:Nbsp dbt:Nervous-system-drug-stub dbt:Phenethylamines dbt:Reflist dbt:Short_description dbt:Technical dbt:Abbrlink dbt:Cascite dbt:Nicotinic_acetylcholine_receptor_modulators dbt:Monoamine_reuptake_inhibitors |
| dcterms:subject | dbc:Chlorobenzenes dbc:Human_drug_metabolites dbc:Secondary_alcohols dbc:Secondary_amines dbc:Nicotinic_antagonists dbc:Phenylethanolamines dbc:Antidepressants dbc:Convulsants dbc:Serotonin–norepinephrine–dopamine_reuptake_inhibitors dbc:Substituted_amphetamines dbc:Tert-butyl_compounds |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Threohydrobupropion (developmental code names BW 494, BW A494U) is a substituted amphetamine derivative—specifically a β-hydroxyamphetamine—and a major active metabolite of the antidepressant drug bupropion (Wellbutrin). Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator, with its metabolites contributing substantially to its activities. Threohydrobupropion exists as two isomers, (1R,2R)-threohydrobupropion and (1S,2S)-threohydrobupropion. Other metabolites of bupropion include hydroxybupropion and erythrohydrobupropion. (en) |
| rdfs:label | Threohydrobupropion (en) |
| owl:sameAs | wikidata:Threohydrobupropion https://global.dbpedia.org/id/Fcghe |
| prov:wasDerivedFrom | wikipedia-en:Threohydrobupropion?oldid=1114277803&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Threohydrobupropion.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Threohydrobupropion |
| is dbo:wikiPageRedirects of | dbr:BW-494 dbr:BW-A494U dbr:BW494 dbr:BWA494U dbr:BW_494 dbr:BW_A494U dbr:Threo-Hydrobupropion dbr:Threo-hydrobupropion |
| is dbo:wikiPageWikiLink of | dbr:Hydroxybupropion dbr:Erythrohydrobupropion dbr:Bupropion dbr:Dextromethorphan/bupropion dbr:BW-494 dbr:BW-A494U dbr:BW494 dbr:BWA494U dbr:BW_494 dbr:BW_A494U dbr:Threo-Hydrobupropion dbr:Threo-hydrobupropion |
| is foaf:primaryTopic of | wikipedia-en:Threohydrobupropion |
